Drug
Futermestotug clinical trials
Also written YH001.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
- YH001
- 4
Studies by the year they started
6 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Eucure (Beijing) Biopharma Co., Ltd (5) · Tracon Pharmaceuticals Inc. (1)
Often tested with
Tested in the same studies.
Toripalimab (2) · Envafolimab (1) · Ciltistotug (1) · Cenzestotug (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses futermestotug is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid TumorsCompletedPhase 1Eucure (Beijing) Biopharma Co., LtdNCT05176509Written as YH001
- A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid TumorsCompletedPhase 1Eucure (Beijing) Biopharma Co., LtdNCT05169697Written as YH002+YH001
- YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic SarcomaActive, not recruitingPhase 1/2Tracon Pharmaceuticals Inc.NCT05448820Written as YH001
- A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid TumorsCompletedPhase 1Eucure (Beijing) Biopharma Co., LtdNCT04357756Written as YH001
- A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnPhase 2Eucure (Beijing) Biopharma Co., LtdNCT05212922Written as YH001 + Toripalimab
- A Study to Evaluate YH001 in Subjects With Advanced Solid TumorsCompletedPhase 1Eucure (Beijing) Biopharma Co., LtdNCT04699929Written as YH001
Codes
What other systems call futermestotug · ClinicalTrials.gg INT017212
- UNII (FDA) LSX3UPC7JYFUTERMESTOTUGOne source FDA
- NCI Thesaurus C176873FutermestotugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LSX3UPC7JY | FUTERMESTOTUG | One source FDA |
| NCI Thesaurus | C176873 | Futermestotug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.